Werewolf Therapeutics
Watertown, United States · Biotechnology, Healthcare, Health Care
Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of
Key facts
- Headquarters
- Watertown, United States
- Employees
- 23
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (HOWL)
- Website
- werewolftx.com
- Company page
Recent activity at Werewolf Therapeutics
- : SEC 8-K (1.01): On August 21, 2026, Werewolf Therapeutics, Inc. entered into a Merger Agreement with Ambros Therapeutics, Inc. and Wave Atlantis Merger Sub, Inc. Under this agreement, Wave Atlantis will merge with Ambros, with Ambros becoming a wholly owned subsidiary of Werewolf. The Merger is structured to qualify as a tax-free reorganization under U.S. federal income tax laws. This strategic move aims to enhance Werewolf's market position and capabilities in the biotechnology sector.
- : SEC 8-K (1.01):
- : SEC 8-K (8.01): On February 24, 2026, Werewolf Therapeutics, Inc. announced via press release its intention to explore strategic alternatives, indicating a possible shift in corporate strategy or potential divestitures. The company has engaged Piper Sandler & Co. as its exclusive financial advisor to assist in this strategic evaluation. This decision may lead to significant changes in the company's operations and is aimed at enhancing shareholder value. The announcement underscores the company's proactive approach towards evaluating its business options in the current market landscape.
- : SEC 8-K (5.02): On February 9, 2026, Timothy W. Trost, the Chief Financial Officer, and Dr. Randi Isaacs, the Chief Medical Officer, agreed to resign from their positions effective February 13, 2026. They are entitled to severance benefits including nine months of base salary and healthcare contributions as per their employment agreements. Additionally, both executives will enter into consulting agreements effective February 16, 2026, at a rate of $250 per hour for up to six months to assist with the transition. Concurrently, on February 12, 2026, Michael Urban was appointed as the new principal financial officer, effective February 13, 2026, bringing prior experience from his roles at various companies including Codiak BioSciences, Inc. and Indigo Ag, Inc.
- : Werewolf Therapeutics Announces Pipeline Update and Strategic Partnership Plans
- : SEC 8-K (8.01): On December 18, 2025, Werewolf Therapeutics, Inc. announced a strategic pipeline update via a press release, highlighting its focus for 2026, including the INDUKINE™ programs. The company is actively seeking strategic partnerships to further develop the promising WTX-124 and WTX-330 INDUKINE programs, supported by recent compelling data from ongoing clinical trials. Notably, preliminary data from the Phase 1/1b clinical trial for WTX-124, announced as of October 30, 2025, demonstrated durable responses in various cancer types. This announcement signifies a potential shift in business strategy and prioritization for the upcoming year, driven by positive clinical trial results and a search for collaborators to enhance development efforts.
- : SEC 8-K (8.01): On December 18, 2025, Werewolf Therapeutics, Inc. issued a press release detailing a pipeline update and strategic overview for 2026, focusing on its INDUKINE programs, specifically the WTX-124 and WTX-330 INDUCINE candidates. The release highlights compelling clinical data from ongoing trials, including a 21% objective response rate in advanced melanoma patients treated with WTX-124. Additionally, the FDA has accepted 18 mg as the recommended dose for further development, indicating a potential registration path for WTX-124. The company is actively seeking strategic partnerships to enhance development efforts, reflecting a strategic positioning for future growth in targeted cancer therapies.
- : Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
- : Werewolf Therapeutics, Inc.
- : Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Werewolf Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2021 | Venture | $72.1M |
| Jan 2021 | Series B | $72.0M |
| Aug 2019 | Venture | $31.6M |
Leadership
- Dan Hicklin, Founder
- Daniel Hicklin, Executive Officer, Director
- Luke Evnin, Director
- Briggs Morrison, Director
- Christoph Westphal, Director
- Sakae Asanuma, Director
- Alon Lazarus, Director
- Patrick Baeuerle, Director
Verified email and direct lines for Werewolf Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Werewolf Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Werewolf Therapeutics in the news
- Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewswire (Jul 31, 2026)
- Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement - Investing News Network (Aug 21, 2026)
- WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy - OncLive (Oct 08, 2025)
- Werewolf Therapeutics Selected for Oral Presentation and to - GlobeNewswire (Oct 30, 2026)
- Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates - GlobeNewswire (May 07, 2026)
- Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives - GlobeNewswire (Feb 24, 2026)
Companies similar to Werewolf Therapeutics
- TuHURA Biosciences · Biotechnology, Healthcare, Health Care, Therapeutics
- Ovid Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Oncotelic Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- CytoDyn · Biotechnology, Healthcare, Health Care, Therapeutics
About Werewolf Therapeutics: questions and answers
What does Werewolf Therapeutics do?
Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of
Where is Werewolf Therapeutics headquartered?
Werewolf Therapeutics is headquartered in Watertown, United States.
How many employees does Werewolf Therapeutics have?
Werewolf Therapeutics has about 23 employees.
Has Werewolf Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Werewolf Therapeutics. The most recent, $72.1M, was in Jan 2021.
Who leads Werewolf Therapeutics?
Dan Hicklin is a Founder at Werewolf Therapeutics.
What is the latest news on Werewolf Therapeutics?
On Aug 21, 2026, SEC 8-K (1.01): On August 21, 2026, Werewolf Therapeutics, Inc. entered into a Merger Agreement with Ambros Therapeutics, Inc. and Wave Atlantis Merger Sub, Inc. Under this agreement, Wave Atlantis will merge with Ambros, with Ambros becoming a wholly owned subsidiary of Werewolf. The Merger is stru
Is Werewolf Therapeutics a public company?
Yes. Werewolf Therapeutics is publicly traded under the ticker HOWL.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy